Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 13/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7643460 | 0.92 | ACE (0.42) | KMT2AL3MBTL1ACE | |
| SCHEMBL7644416 | 0.83 | KMT2A (0.47) | KMT2AL3MBTL1ACELMNA | |
| SCHEMBL7404464 | 0.81 | KMT2A (0.43) | KMT2AL3MBTL1ACEACE2LMNA | |
| SCHEMBL7404462 | 0.81 | KMT2A (0.43) | KMT2AL3MBTL1ACEACE2LMNA | |
| SCHEMBL15251959 | 0.77 | ACE (0.64) | KMT2AL3MBTL1ACEACE2 | |
| SCHEMBL15251960 | 0.77 | ACE (0.64) | KMT2AL3MBTL1ACEACE2 | |
| SCHEMBL7642427 | 0.76 | KMT2A (0.40) | KMT2AL3MBTL1ACELMNA | |
| SCHEMBL7644425 | 0.73 | PEPD (0.38) | KMT2AL3MBTL1LMNA | |
| SCHEMBL7400095 | 0.73 | ACE (0.51) | KMT2AACEACE2LMNA | |
| SCHEMBL11284016 | 0.72 | ACE (0.56) | KMT2AL3MBTL1ACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6468977-B1 | COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS | APOTEX INC. (CA) | 2002-10-22 | — | — | US | disclosed |
| US-6162791-A | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes | APOTEX INC. (CA) | 2000-12-19 | — | — | US | disclosed |